Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-term open-label extension study of Hengli botulinum toxin type A injection for lower limb spasticity in children with spastic cerebral palsy
CTR20231319Phase 3Completed
- Sponsor
- Lanzhou Biotechnology Development
- Start
- May 2023
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 3 trial of lanbotulinumtoxin-A in cerebral palsy (CP), lower extremity spasticity, sponsored by Lanzhou Biotechnology Development. Started May 2023; status: completed.
02
Drugs
lanbotulinumtoxin-A
03
Conditions
cerebral palsy (CP)lower extremity spasticity
Beyond the preview
Go deeper on CTR20231319.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20231319.